Modeling computational studies of modified drug molecules binding to the LRRK2 protein in the treatment of Parkinson’s disease

• Autorzy: Shah H. , Darsey J. A.
• Języki publikacji: EN

Abstrakty

EN

Parkinson’s disease is a neurodegenerative and progressive disease of the central nervous system. It affects more than 10 million patients worldwide and the symptoms allow for little to no control for movement. These symptoms appear because the chemical messenger dopamine is being made in small quantities from impaired cells. However, the disease often forms when there is a mutation in the LRRK2 gene, as the functions of the protein become abnormal. The IC50 value is essential information about molecules because it measures their effectiveness. The goal of this research was to design molecules with a lower IC50 value. This was first done by modeling molecules on the molecular modeling program, Gaussian 09. Modifications were made to molecules that were said to bind to the LRRK2 protein. Modifications ranged from adding a single atom or replacing atoms with groups. After running these molecules on the program, the total energy was found. Using the equation found from the correlation between 1/IC50 and the total energy, the IC50 value was predicted for each of the modified molecules. Many of the modified molecules portrayed a positive percent difference between the original IC50 value and the new one. This saves both time and money because the molecules with lower IC50 values can be made, preserving the resources. After creating the molecule with a low IC50 value, further experimental procedures can be taken; this is a large step in assisting researchers to reach a potential treatment because it is more efficient.

Słowa kluczowe

EN

LRRK2 proteins; Parkinson; Computational Modeling; IC50; Density Functional Theory; DFT

• Wydawca: Polish Society for Biomaterials in Cracow
• Czasopismo: Engineering of Biomaterials
• Rocznik: 2018
• Tom: Vol. 21, no. 145
• Strony: 2--7
• Opis fizyczny: Biblogr. 10 poz., rys., tab.

Twórcy

autor

Shah H.

• Center for Molecular Design and Development, University of Arkansas at Little Rock, Little Rock, Arkansas USA 72204

autor

Darsey J. A.

• Center for Molecular Design and Development, University of Arkansas at Little Rock, Little Rock, Arkansas USA 72204

Bibliografia

• References
• [1] R. R. Neubig, International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55 (4) (2003) 597-606.
• [2] What Is Parkinson’s? (2018, March 13). Retrieved April 15, 2018, from http://www.parkinson.org/understanding-parkinsons/ what-is-parkinsons What is Parkinson’s Disease. (2016). Retrieved December 11, 2016, from http://www.pdf.org/about_pd
• [3] Renter, E. (2012, October 30). Monsanto’s Roundup, Glyphosate Linked To Parkinson’s And Similar Diseases. Retrieved November 12, 2016, from http://naturalsociety.com/monsantos-roundup-glyphosate-parkinsons-neurodegenerative/
• [4] Reina N. Fuji, Michael Flagella, Miriam Baca, Marco A. S. Baptista, Jens Brodbeck, Bryan K. Chan, Brian K. Fiske: Effect of selective LRRK2 kinase inhibition on nonhuman primate lung Lee H, Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Science Translational Medicine 04 Feb 2015: Vol. 7, Issue 273, pp. 273ra15.
• [5] The Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69 (2007) 1480-1490.
• [6] The Science of Parkinson’s. (2012). Retrieved December 11, 2016, from http://tanz.med.utoronto.ca/page/science-parkinsons.
• [7] Shah H., Darsey J.: Computational Modeling Studies of the LRRK2 Protein in the Mechanism of Parkinson’s Disease. Curr. Trends Biomedical Eng & Biosci. 7(1) (2017) 1-6.
• [8] Gilligan P.J.: Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson’s Disease. Current Topics in Medicinal Chemistry 15 (10) (2015) 927-938.
• [9] LRRK2 gene - Genetics Home Reference. (2017). Retrieved January 23, 2017, from https://ghr.nlm.nih.gov/gene/ LRRK2#conditions
• [10] Truong DD., Bhidayasiri R., Wolters E.: Management of non- -motor symptoms in advanced Parkinson disease. J Neurol Sci. 266 (2008) 216-228.

Uwagi

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2018).